

# EXPAND ACCESS TO BIOMARKER TESTING IN PENNSYLVANIA


THE RIGHT TREATMENT AT THE RIGHT TIME

## WHAT IS BIOMARKER TESTING?


**Biomarker testing is often used to help determine the best treatment for a patient.**

- It is the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker.
- Biomarker testing is an important step for accessing precision medicine, including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients.
- While most current applications of biomarker testing are in oncology and autoimmune disease, there is research underway to benefit patients with other conditions including heart disease, neurological conditions like Alzheimer's disease, infectious disease and respiratory illness.

## THE IMPORTANCE OF BIOMARKER TESTING



Of oncology drugs launched in the past five years require or recommend biomarker testing prior to use <sup>1</sup>



Of cancer clinical trials involved biomarkers <sup>2</sup>

## BIOMARKER TESTING & HEALTH EQUITY

- **Not all communities in Pennsylvania are benefitting from the latest advancements in biomarker testing and precision medicine.**
  - Patients who are older, Black, uninsured or Medicaid-insured, are less likely to be tested for certain guideline-indicated biomarkers.
  - There are lower rates of testing in community settings versus academic medical centers.

## THE BOTTOM LINE

**Access to appropriate biomarker testing can help to achieve:**

- better health outcomes
- improved quality of life
- reduced costs

**Insurance coverage for biomarker testing is failing to keep pace with innovation and advancement in treatment:**


- Without action, this could increase existing disparities in health outcomes by race, ethnicity, income and geography.

**Arizona, Illinois, Louisiana and Rhode Island have recently passed legislation to expand coverage of comprehensive biomarker testing.**



Of oncology providers reported that insurance coverage is a **significant or moderate barrier** to appropriate biomarker testing for their patients <sup>3</sup>

**In PA:**



Of commercial insurance plans provide coverage that is more restrictive than National Comprehensive Cancer Network guidelines <sup>4</sup>

# SUPPORTERS OF PENNSYLVANIA BIOMARKER TESTING LEGISLATION



<sup>1</sup>Global Oncology Trends 2021. IQVIA Institute; June 2021.

<sup>2</sup>The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications. Personalized Medicine Coalition, 2019.

<sup>3</sup>ACS CAN. "Survey Findings Summary: Understanding Provider Utilization of Cancer Biomarker Testing Across Cancers." December 2021.

<sup>4</sup>Wong WB, Anina D, Lin CW, and Adams D. Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors. Per Med 2022; 10.2217/pme-2021-0174.

For more information please contact:

Donna Greco, ACS CAN Pennsylvania Government Relations Director

✉ [Donna.Greco@cancer.org](mailto:Donna.Greco@cancer.org)

☎ 717.534.1075